Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
"Is Boris preparing to flounce out of the cabinet?" Not my question, but that of one of his senior ministerial colleagues.
The funeral of the Cranberries lead singer is due to take place today in her hometown church.
Rupert Murdoch faces a fresh setback in his bid to take full control of Sky through 21st Century Fox.